MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2025 International Congress

    The Bjorn Moller Research Repository: A Resource for Movement Disorders Research

    S. Schaffner, A. Kuan, D. Felix, S. Appel-Cresswell (Vancouver, Canada)

    Objective: To build a repository of longitudinally collected biological samples and clinical, demographic, and lifestyle data from individuals with Parkinson’s disease (PD) and other movement…
  • 2025 International Congress

    Methodological considerations supporting a time-to-event primary endpoint in the PADOVA study in early-stage Parkinson’s disease participants on stable symptomatic treatment

    N. Pross, G. Pagano, D. Trundell, J. Anzures-Cabrera, T. Simuni, K. Marek, N. Pavese, K. Seppi, F. Stocchi, R. Postuma, A. Monnet, L. Rutten-Jacobs, G. Respondek, L. Boak, G. Kerchner, P. Brundin, H. Svoboda, T. Nikolcheva, A. Bonni (Basel, Switzerland)

    Objective: To provide the methodological rationale for using a time-to-event (TTE) primary endpoint in the PADOVA study. Background: The use of symptomatic medications represents a…
  • 2025 International Congress

    Mathematical and Computational Modeling Prototype to Understand the Evolution of Parkinson’s disease using Four Differential Equations

    G. Sa, A. Rodrigues Tavares, M. Silva Bissaco (Mogi das Cruzes, Brazil)

    Objective: Apply four differential equations to generate projections considering the effect of dopamine on Parkinson’s disease progression, leading to the development of an initial prototype…
  • 2025 International Congress

    Quality of Life Improvements in Parkinson’s Disease for Those Treated with Photobiomodulation Plus Exercise: A Sham-Controlled Study

    A. Saltmarche, O. Hares, A. Liebert, B. Bicknell, M. Naeser, G. Heller, J. Sykes, K. Togeretz, A. Namini, G. Herkes (Toronto, Canada)

    Objective: To assess whether exercise alone, or exercise combined with photobiomodulation (PBM) can improve the health-related quality of life (QoL) for people with Parkinson’s disease…
  • 2025 International Congress

    CAP-003, a CNS-targeted IV-delivered AAV Gene Therapy Developed for Patients with Parkinson’s Disease associated with GBA1 Mutations

    K. Mcdowell, R. Ressler, M. Flynn, B. Wheeler, L. Grigoryeva, A. Armendariz, H. Acharya, P. Denis, J. Granados, P. Tchourilov, C. Pedeferri, M. Brandabur, S. Tole, N. Goeden, N. Flytzanis (Thousand Oaks, USA)

    Objective: CAP-003 is a next-generation gene therapy candidate, comprising a novel brain-tropic capsid paired with hGBA1 cargo, that was developed for administration as a single…
  • 2025 International Congress

    A Phase 2 Study of Risvodetinib in Untreated Parkinson’s Disease

    M. Werner, C. Meyer, E. Mancino, C. Klint, J. Pellecchia, A. Mcgarry, K. Kieburtz, C. Olanow (Atlanta, USA)

    Objective: Risvodetinib was evaluated in a randomized, double-blind, placebo controlled Phase 2 trial at three doses to determine the safety and tolerability in patients with…
  • 2025 International Congress

    Effect of Allogeneic Bone-Marrow Derived Mesenchymal Stem Cell Therapy on Quality of Life in Patients with Parkinson’s Disease

    C. Onuigbo, J. Martinez-Lemus, T. Thomas, E. Tharp, J. Suescun, C. Green, T. Ellmore, E. Rodarte Rascon, R. Ritter, M. Schiess (Houston, USA)

    Objective: To assess the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions on the quality of life (QoL) of patients with…
  • 2025 International Congress

    A Systematic Site Selection Approach to Ensure Efficient and Diverse Participant Recruitment to a Large-Scale Multi-Arm, Multi-Stage Platform Trial for Parkinson’s

    G. Mills, M-L. Zeissler, O. Bandmann, R. Barker, J. Carpenter, S. Collins, J. Duffen, S. Gandhi, L. Houlden, C. Gonzalez-Robles, C. Mcalpine, K. Mcfarthing, C. Pugh, A. Schapira, A. Schrag, C. Shakeshaft, T. Foltynie, C. Carroll (London, United Kingdom)

    Objective: To select up to 40 delivery sites to successfully recruit and retain a participant population representative of people with Parkinson’s disease (PwP) in the…
  • 2025 International Congress

    EJS ACT-PD: An Ongoing Initiative to Support Innovation and Sustainability of a Multi-Arm, Multi-Stage Platform Trial for Parkinson’s Disease

    G. Mills, C. Gonzalez-Robles, M-L. Zeissler, O. Bandmann, R. Barker, J. Carpenter, S. Collins, J. Duffen, S. Gandhi, K. Mcfarthing, A. Schapira, A. Schrag, C. Carroll, T. Foltynie (London, United Kingdom)

    Objective: To provide continued consortium expertise to provide ongoing innovation and long-term sustainability in a multi-arm, multi-stage (MAMS) disease modification trial for Parkinson’s disease (PD).…
  • 2025 International Congress

    Ecologically Valid, Ambient, Longitudinal, and Unbiased Assessment of Treatment Efficacy in Parkinson’s Disease (EVALUATE-PD)

    J. Kaye, E. Leonard, L. Talman, N. Rodrigues, Z. Beattie (Portland, USA)

    Objective: To determine the feasibility of using in-home digital biomarkers (DBs) and activity monitoring for clinical trials and studies of early Parkinson’s Disease (PD) and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 22
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley